{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:55:36Z","timestamp":1792612536439,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["dldjournalonline.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.dld.2014.07.019","type":"journal-article","created":{"date-parts":[[2014,8,17]],"date-time":"2014-08-17T09:45:42Z","timestamp":1408268742000},"page":"963-968","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease"],"prefix":"10.1016","volume":"46","author":[{"given":"Vito","family":"Annese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Vecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Bossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Daperno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Rizzello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rispo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Saibeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Armuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Biancone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Castiglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Comberlato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Cucchiara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"D\u2019Inc\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gionata","family":"Fiorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Fries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gionchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Latella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gimmy","family":"Meucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambrogio","family":"Orlando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Papi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Principi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2014.07.019_bib0005","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1182\/blood-2012-04-425744","article-title":"Biosimilars: what clinicians should know","volume":"120","author":"Weise","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.dld.2014.07.019_bib0010","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/nbt.2447","article-title":"Setting the stage for biosimilar monoclonal antibodies","volume":"30","author":"Schneider","year":"2012","journal-title":"Nature Biotechnology"},{"key":"10.1016\/j.dld.2014.07.019_bib0015","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/ajg.2010.392","article-title":"The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn's and Colitis organization: when to start, when to stop, which drug to choose, and how to predict response?","volume":"106","author":"D\u2019Haens","year":"2011","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2014.07.019_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.dld.2010.07.010","article-title":"The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) clinical practice guidelines: the use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease","volume":"43","author":"Orlando","year":"2011","journal-title":"Digestive and Liver Disease"},{"key":"10.1016\/j.dld.2014.07.019_bib0025","first-page":"CD008794","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","author":"Singh","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.dld.2014.07.019_bib0030","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1053\/j.gastro.2013.11.012","article-title":"Does anti-TNF therapy cost so many COINs?","volume":"146","author":"Roblin","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2014.07.019_bib0035","unstructured":"EMA guideline \u201cSimilar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues\u201d. EMEA\/CHMP\/BMWP\/42832\/2005."},{"key":"10.1016\/j.dld.2014.07.019_bib0040","unstructured":"EMA guideline \u201cSimilar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues\u201d. EMEA\/CHMP\/BWP\/49348\/2005."},{"key":"10.1016\/j.dld.2014.07.019_bib0045","unstructured":"EMA guideline on similar biological medicinal products containing monoclonal antibodies: non-clinical and clinical issues. CHMP\/BMWP\/403543\/2010."},{"key":"10.1016\/j.dld.2014.07.019_bib0050","unstructured":"http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2011\/06\/news_detail_001282.jsp&murl=menus\/news_and_events\/news_and_events.jsp&mid=wc0b01ac058004d5c1."},{"key":"10.1016\/j.dld.2014.07.019_bib0055","unstructured":"Press release: EMA recommends approval of first two monoclonal antibody biosimilars. EMA\/390722\/2013."},{"key":"10.1016\/j.dld.2014.07.019_bib0060","unstructured":"Biosimilar News. World's first biosimilar antibody is approved in Korea [14.11.12]."},{"key":"10.1016\/j.dld.2014.07.019_bib0065","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1136\/gutjnl-2012-303824","article-title":"Biosimilars in IBD: hope or expectation?","volume":"62","author":"Gecse","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.dld.2014.07.019_bib0070","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.crohns.2013.03.011","article-title":"ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD)","volume":"7","author":"Danese","year":"2013","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1016\/j.dld.2014.07.019_bib0075","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4321\/S1130-01082013000100006","article-title":"Joint position statement by \u201cSociedad Espa\u00f1ola de Patolog\u00eda Digestiva\u201d (Spanish Society of Gastroenterology) and Sociedad Espa\u00f1ola de Farmacolog\u00eda\u201d (Spanish Society of Pharmacology) on biosimilar therapy for inflammatory bowel disease","volume":"105","author":"Arg\u00fcelles-Arias","year":"2013","journal-title":"Revista Espanola de Enfermedades Digestivas"},{"key":"10.1016\/j.dld.2014.07.019_bib0080","series-title":"Process scale bioseparations for the biopharmaceutical industry","first-page":"507","article-title":"Making changes to a biopharmaceutical manufacturing process during development and commercial manufacturing","author":"Wojciechowski","year":"2006"},{"key":"10.1016\/j.dld.2014.07.019_bib0085","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1745-6215-12-106","article-title":"Through the looking glass: understanding non-inferiority","volume":"12","author":"Schumi","year":"2011","journal-title":"Trials"},{"key":"10.1016\/j.dld.2014.07.019_bib0090","series-title":"New pharmacovigilance rules in the EU and their impact on biosimilars and automatic substitution","author":"Str\u00e4ter","year":"2011"},{"key":"10.1016\/j.dld.2014.07.019_bib0095","unstructured":"AIFA. Position paper su farmaci biosimilari. http:\/\/www.agenziafarmaco.gov.it\/it\/content\/position-paper-sui-farmaci-biosimilari-28052013 [28.05.13]."},{"key":"10.1016\/j.dld.2014.07.019_bib0100","series-title":"Innovation in the biopharmaceutical pipeline: a multidimensional view","author":"Long","year":"2013"},{"key":"10.1016\/j.dld.2014.07.019_bib0105","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/ajg.2011.73","article-title":"Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2014.07.019_bib0110","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn's disease","volume":"340","author":"Present","year":"1999","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.07.019_bib0115","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMe048001","article-title":"Closing fistulas in Crohn's disease\u2014should the accent be on maintenance or safety?","volume":"350","author":"Fiocchi","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.07.019_bib0120","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2014.07.019_bib0125","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1136\/gutjnl-2011-300904","article-title":"New therapies for inflammatory bowel disease: from the bench to the bedside","volume":"61","author":"Danese","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.dld.2014.07.019_bib0130","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/gut.2009.183095","article-title":"Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis","volume":"59","author":"Seow","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.dld.2014.07.019_bib0135","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/gut.2010.236869","article-title":"Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment","volume":"61","author":"VandeCasteele","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.dld.2014.07.019_bib0140","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/ibd.21839","article-title":"Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease","volume":"18","author":"Pariente","year":"2012","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2014.07.019_bib0145","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ajg.2012.363","article-title":"Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis","volume":"108","author":"Nanda","year":"2013","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2014.07.019_bib0150","unstructured":"http:\/\/www.evaluategroup.com\/Universal\/View.aspx?type=Story&id=320129."},{"key":"10.1016\/j.dld.2014.07.019_bib0155","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","article-title":"A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study","volume":"72","author":"Park","year":"2013","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.dld.2014.07.019_bib0160","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","article-title":"A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study","volume":"72","author":"Yoo","year":"2013","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.dld.2014.07.019_bib0165","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2014.07.019_bib0170","unstructured":"http:\/\/www.hc-sc.gc.ca\/dhp-mps\/prodpharma\/sbd-smd\/drug-med\/sbd_smd_2014_inflectra_159493-eng.php."}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865814004460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865814004460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,30]],"date-time":"2018-09-30T13:51:54Z","timestamp":1538315514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865814004460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S1590865814004460"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2014.07.019","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2014.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}